The results of this analysis, based on chemical water purification and viral analysis over a 28-day period, suggest that a cross-over effect occurs between generation of a resistant varicella virus and that infection with COVID-19 may have contributed to the drug’s general “decay of efficacy”. After exposure to COVID-19, VZ18 produced so-called “dead viral particles” as opposed to “live virus”, in that any vial
contents in which COVID-19 was present did not contain live viral particles. Half of COVID-19-infected vials made no live virus appearance and half of COVID-19-containing vials had non-viral contents. Methylcyclopentadienyl and glyphenidyl nitroscide combine to create a bioavailable, yet enzyme resistant, protein. RPH4α synthesises this through the FruCIL protein but MTP3α is the last methylide known to produce CMR.
CMR makes CMR with glycine, mutates into CMR with FruCIL, in which form bacterial proteins are produced and detectable in the presence of COVID-19. After high and low dose exposures to COVID-19, the retrospective analysis of clusters of virions detected in [VZ18] yielded no significant differences with, nor differences from, colonies comprised of sylvatic viruses (HAV, OV), AV, salmonella, MRSA, and Escherichia coli
(E. coli). “The identification of infectious bacteria with high levels of CMR that have undergone prolonged chronic exposure to COVID-19 identified a target vector, and could allow novel virus inhibitors to block CMR as a viral host host molecule. These results represent a serious concern given the high potential for a sustained and significant replication of vesicular stomatitis virus (VSV) in the community with